Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy
      Google Scholar   
Citation:
Blood vol 134 (Supplement 1) abstract 1366
Meeting Instance:
ASH 2019
Year:
2019
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
Older Adult    
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA189823, U24CA196171; U10CA180820 (ECOG-ACRIN); U10CA180888, UG1CA233270 (SWOG)  
Corr. Author:
 
Authors:
                   
Networks:
LAPS-IL036, LAPS-MA036, LAPS-MO011, LAPS-TN008, NC002, OH070, WINCORP   
Study
Alliance-A041701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2/3
Keywords: